Compare CHCO & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHCO | VRDN |
|---|---|---|
| Founded | 1957 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1995 | 2014 |
| Metric | CHCO | VRDN |
|---|---|---|
| Price | $143.01 | $21.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $132.50 | $35.46 |
| AVG Volume (30 Days) | 78.0K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 13.18 | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $5.16 | $13.73 |
| Revenue Next Year | $3.12 | $279.00 |
| P/E Ratio | $31.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $113.21 | $13.18 |
| 52 Week High | $148.99 | $34.29 |
| Indicator | CHCO | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 46.44 |
| Support Level | $141.72 | $21.40 |
| Resistance Level | $147.01 | $23.84 |
| Average True Range (ATR) | 1.88 | 0.88 |
| MACD | -0.36 | -0.24 |
| Stochastic Oscillator | 16.99 | 28.87 |
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.